A 1 -A 2 9 8 OBJECTIVES: To describe health resource utilization (HRU) patterns among patients with systemic lupus erythematosus (SLE) prescribed belimumab in U.S clinical practice settings. METHODS: OBSErve (BLM117295) is a multi-center retrospective medical chart review study. Ninety-two rheumatologists from nonacademic-centers in the U.S randomly identified adult SLE patients in their practice who had received at least 8 infusions of belimumab (10mg/kg) as part of usual-care. Index-date is the date of the first belimumab infusion. Physicians assessed the following data corresponding to the 6 months pre-and post-index periods: patient demographics, comorbidities, SLE disease characteristics/ outcomes, and HRU (hospitalization/ER/office-visits, ancillary care (physical/occupational therapy/home health), medications). Patterns of HRU in the 6 months pre-and post-index period are reported from univariate (comparative) analysis and two-sided tests of significance (p<0.05). RESULTS: Physicians abstracted 501 eligible patient-charts (mean age:41.3yrs, female:89%, Caucasian:53%, black/African-American:24%, Hispanic:18%, other:5%; Medicare:13%, Medicaid:14%, commercial-insurance:62%; diagnosed with SLE <5 yrs ago:56%); 3%/77%/20% had mild/moderate/severe disease at baseline, per physician judgment. In the pre-index period, concomitant medications included oral steroids(78%), antimalarials(70%), immunosuppressants(61%) and NSAIDs(16%). In post-index period, among those on oral steroids, 9% discontinued steroids and 77% decreased the dose. Percentage of patients with >1 hospitalization (pre-index:5%;post-index:2%;p=0.03), >1 ER visits (preindex:15%;post-index:6%;p=0.001), >1 unscheduled treating physician visits (preindex:52%;post-index:30%;p<0.001), and those receiving any ancillary care (preindex:15%;post-index:6%;p=0.001) decreased from pre-index to post-index period.
OBJECTIVES:
Treating the approximately 100,000 patients in the United States today with sickle cell disease (SCD) can be costly. Identifying the main cost drivers of SCD is essential to developing appropriate interventions and improving patient outcomes. Real-world insights into the main cost drivers of SCD were gathered from the perspective of payers and physicians actively treating patients. METHODS: A systematic literature review was conducted on resource use and cost drivers associated with SCD, guiding our questionnaire development. Three physicians from academic and private practice and nine payers (medical, pharmacy or case management directors of large regional or national plans with commercial, Medicaid and/or managed Medicaid patients) were interviewed about their SCD patient management, resource utilization, and cost drivers experiences. RESULTS: Evidence from the published literature suggests that a small number of patients account for the majority of resource utilization and costs. Studies assessing resource utilization by SCD patients reported that 25% of patients accounted for 75% (Medicaid) and 83% (privately insured) of costs, and nearly 80% of total inpatient days. Physicians and payers indicated that about 10-30% of patients are responsible for the majority of costs. Payers also revealed that SCD patients can have "catastrophic" costs, and rank among the plan's top 20 most costly patients. Payers and physicians all reported that SCD patients faced barriers to accessing primary care, leading to hospitalization and emergency department overuse. Barriers included low Medicaid reimbursement rates, lack of transportation, and low health care literacy. CONCLUSIONS: Results from this systematic literature review and interviews with physicians and payers identify barriers in access to care as a key driver for hospitalization and emergency department overuse by SCD patients. This suggests that effectively designed disease management programs can help patients avoid acute care utilization, delivering better patient care with lower costs. and CWH (411 WOI, 42 WI) were without inhibitors. Use of on-demand and prophylaxis treatment was evenly distributed among PWH (180 on-demand, 203 prophylaxis); most CWH were on prophylaxis (87 on-demand, 335 prophylaxis). Mean/median bleeds per year were higher in PWH WOI on prophylaxis (14.9/5) than on-demand (10.3/2), but lower in WI on prophylaxis (5.6/2) than on-demand (15.6/7). Higher-risk activities were reported more for PWH on prophylaxis (15% vs. 8%) and with decreasing annual bleed rates (15%-9%). Mean/median annual bleeds were higher in CWH WOI on on-demand (7.5/3) than prophylaxis (5.2/3) and in WI on prophylaxis (12.1/8) than on-demand (9.2/6). Mean annual haemophilia treatment centre (HTC) visits were slightly higher on prophylaxis for PWH (prophylaxis 4.5, on-demand 3.7) and CWH (prophylaxis 5.6, on-demand 4.8). For CWH, median HTC visits increased with increasing bleed frequency (2-5/year). Nurse involvement in haemophilia management was more frequently reported by PWH on prophylaxis (57%) than on-demand (45%). Nurse (37%-57%), social worker (9%-32%), and physiotherapist (20%-37%) involvement increased with bleed frequency in PWH. CWH WI reported more nurse involvement on prophylaxis (71%) than on-demand (57%) but less social worker involvement (8% vs. 29%); physiotherapists were more frequently involved for CWH WOI on prophylaxis (34%, on-demand 23%). CONCLUSIONS: HTC utilisation was higher for PWH/CWH on prophylaxis; for CWH, bleed frequency increased utilisation. Involvement of physiotherapy and social work was less than expected for PWH/CWH, but could positively impact bleed rate; and, overall utilization deserves further study. . PWH reporting impacts on intimacy were more likely to have discussed intimacy with the HTC, but less likely to report the discussions as very helpful. More parents reporting NEs telling friends reported impacts on siblings (28% vs 18%). Haemophilia management including nurses and social workers was more often reported for PWH with any NE. More PWH reporting NEs with relationships or friends reported treatment for psychological conditions. Parents reporting work-related NEs reported more mean/median HTC visits per year (6.3/3 vs 4.1/2). Social worker involvement and treatment for psychological conditions were more frequent in parents with NEs related to work or friends. CONCLUSIONS: PWH with one NE were more likely to report other NEs. PWH/parents with NEs reported greater social worker involvement and treatment for psychological conditions. Further studies are needed to assess temporal relationships between NEs and HTC visits/advice, and support the relevance of timely social work and psychological counselling in comprehensive care.
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ASSOCIATIONS BETWEEN INHIBITORS, TREATMENT REGIMEN, AND BLEED FREQUENCY AND HEALTH CARE PRACTITIONER UTILISATION IN THE HAEMOPHILIA TREATMENT CENTRE (HTC): GLOBAL RESULTS FROM THE HAEMOPHILIA EXPERIENCES, RESULTS AND OPPORTUNITIES (HERO) STUDY
PSY87 ASSOCIATIONS BETWEEN NEGATIVE IMPACT ON EMPLOYMENT OR RELATIONSHIPS AND HAEMOPHILIA TREATMENT CENTRE (HTC) AND HEALTH CARE PRACTIONER UTILISATION: GLOBAL RESULTS FROM THE HAEMOPHILIA EXPERIENCES, RESULTS AND OPPORTUNITIES (HERO) STUDY
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BURDEN OF DISEASE OF PAIN IN RUSSIA: RESULTS FROM 2011 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)
Sternbach N 1 , Chapnick J 2 , Mould-Quevedo J 3 1 Kantar Health, New York, NY, USA, 2 Kantar Health, Princeton, NJ, USA, 3 Pfizer, Inc., New York, NY, USA OBJECTIVES: Pain is not a disease, but might be a symptom of a disease, the effect of a disease or an accident. It pervades a person's daily life activities, social interaction and productive hours. It has powerful psychological and social consequences. In Russia, there are no solid estimates of the magnitude of the condition. This study is aimed to assess co-morbidity, quality of life (QOL), work/productivity loss, and resource utilization in Russian urban adults with pain. METHODS: Patients' self-reported data were collected from 2011 National Health and Wellness Survey (NHWS). Survey represented major urban areas in Russia. QOL was measured by the physical (PCS) and mental (MCS) component summary scores of the (SF-12v2). Loss of work/productivity was measured by the Work Productivity and Activity Impairment instrument. Medical resource utilization was measured by health care provider, ambulance request and hospitalization in the past 6 months. RESULTS: Of the 10,039 adult respondents, 2,670 (28%) reported to experience pain over the past month (17% mild, 54% moderate and 28% severe) -35% not receiving medication at all. Average age of patients experiencing pain was 41.5 years. Pain group reported more comorbidities (headaches 77%, sleep difficulties 54%, insomnia 47%, heartburn 45%, depression 39%, high blood pressure 33%), lower mean scores of PCS (43.4 vs.47.8) and MCS (40.0 vs. 45.0), more patients visited health care providers (83% vs. 67%), and a higher percentage were hospitalized (13% vs. 8%) over the past 6 months compared to no experiencing pain group. Furthermore, pain group reported 35.9% impairment in daily activity compared to 23.0% in no experiencing pain group. All mentioned differences were statistically significant (p < 0.05) and all percentages or means are projected values. CONCLUSIONS: From Russian NHWS results, patients experiencing pain suffer from impairment in QOL, work/productivity loss and more co-morbidities. Findings indicate there is still an unmet medical need in Russian patients with pain.
PSY89 TREATMENT OPTIONS IN OBESITY: IS CLINICAL DEVELOPMENT KEEPING UP WITH AN EXPANDING POPULATION?
Hay JA, Barber R, Kusel J, Wilson TJ Costello Medical Consulting Ltd., Cambridge, UK OBJECTIVES: The occurrence of obesity in the UK is rapidly increasing, and is associated with significant health problems and economic costs. Despite this, there is currently only one drug recommended by NICE for the treatment of obesity. The purpose of the study was to examine whether the clinical development of obesity treatments is keeping up with the increasing obese population in the UK. METHODS: Adult obesity prevalence data for England were obtained from the 2011 Health Survey for England Trend Tables. Total economic costs were obtained from the National Obesity Observatory. ClinicalTrials.gov was searched for the number of clinical trials investigating drug and device interventions for obesity initiated yearly from database inception to the 17th of January 2013. Results were reviewed to exclude trials investigating dietary supplements, behavioural changes, dietary changes, and those without a UK centre. RESULTS: The prevalence of obese adults in England has risen from 14.9% (1993) to 24.8% (2011). This has been associated with an estimated increase in total costs to the UK of £2.6 billion (1998) to £15.8 billion (2007) . Since 2000, 46 trials have been initiated investigating treatments for obesity. The number of clinical trials initiated yearly has increased since 2000; however recent years have seen a decline. 1 trial was initiated in 2000, generally increasing up until 2010 when 8 trials were initiated. 2011 and 2012 both saw a dip in the number of initiated trials, with only 3 trials started in 2012. CONCLUSIONS: The prevalence and economic burden of obesity has increased drastically in the UK over the past 18 years. The rate of clinical development has also increased; however, this rate is low in relation to the significance of this health problem and the increase in the obese population. These results highlight the need for further clinical development in treating obesity.
PSY91
IMPACTS OF BLACK BOX WARNING, NATIONAL COVERAGE DETERMINATION, AND RISK EVALUATION AND MITIGATION STRATEGIES ON THE INPATIENT ON-LABEL AND OFF-LABEL USE OF ERYTHROPOIESIS-STIMULATING AGENTS
Seetasith A, Holdford DA Virginia Commonwealth University, Richmond, VA, USA OBJECTIVES: This study aims to quantify the impact of (1) black box warning, (2) CMS National Coverage Determination (NCD), and (3) Risk Evaluation and Mitigation Strategies (REMS) on erythropoiesis-stimulating agents (ESAs) on-label and off-label utilization patterns among adult inpatients. METHODS: Electronic health records in Cerner HealthFact database from January 2005 to June 2011 were used. Eligible patients for ESA prescribing were categorized using ICD-9-CM codes and medication information. The three patient categories were (1) on-label (ONS, conditions approved by the FDA); (2) off-label supported (OFS, strong clinical evidence for use in unapproved indications); and (3) off-label unsupported (OFU, low/no evidence supporting use in unapproved indications). The likelihood of receiving ESAs was assessed using a generalized estimating equation approach with binary logistic regression technique, clustering for hospitals, and controlling for potential confounders. RESULTS: We identified 730,421 patients with ONS conditions (33,004 users, 4.5%), 505, 658 with OFS conditions (5,140 users, 1.0%), and 558,917 patients with OFU conditions (4,491 users, 0.8%). Black box warning and REMS had no impact on the odds of receiving ESAs. There was a significant decline in all three use categories the month following NCD. ONS patients were 13% less likely to receive ESAs (OR 0.867, 95% CI 0.762, 0.986, p = 0.0299). OFS patients were 20% less likely (OR 0.799, 95% CI 0.716, 0.891, p < 0.0001) and OFU patients were 38% less likely to receive ESAs (OR 0.622, 95% CI 0.474, 0.817, p = 0.0006). Age, gender, race, source of payment, admission type, clinical complexity, discharge disposition, and hospital size were significantly associated with on-label and off-label use. CONCLUSIONS: We demonstrated the relative impact of three safety interventions on on-label and off-label ESA use in the hospital settings. Reimbursement change may have unintentionally reduced the likelihood of receiving ESAs in patients who could have otherwise benefited.
PSY92 AMBULATORY DIAGNOSIS AND TREATMENT OF NON-MALIGNANT PAIN IN THE UNITED STATES, 2000-2010
Daubresse M 1 , Chang HY 1 , Viswanathan S 1 , Yu Y 1 , Shah N 2 , Stafford RS 3 , Kruszewski S 4 , Alexander GC 1 1 Hopkins School of Public Health, Baltimore, MD, USA, 2 Mayo Clinic, Rochester, MN, USA, 3 Stanford University, Palo Alto, CA, USA, 4 Stefan P. Kruszewski, M.D. & Associates, P.C., Harrisburg, PA, USA OBJECTIVES: Escalating rates of prescription opioid use and abuse have occurred in the context of efforts to improve the identification and management of nonmalignant pain. To characterize the diagnosis and management of nonmalignant pain in ambulatory, office-based settings between 2000 and 2010. METHODS: Serial cross-sectional and multivariate regression analyses of the National Ambulatory Medical Care Survey (NAMCS), a nationally representative audit of office-based physician visits. The main outcome measures were 1) Annual volume of visits among adults with a primary symptom or diagnosis of pain, and 2) prescription opioid and non-opioid pharmacologic therapy in visits limited to new musculoskeletal pain. RESULTS: Primary symptoms or diagnoses of pain consistently represented one-fifth of visits, varying less than 2% from 2000 through 2010. Patient-reported pain comprised 17% to 19% of visits, whereas provider diagnoses of pain increased nearly 50% from 2000 (5.7% of visits with pain as a primary diagnosis) to 2010 (8.5%). Among all pain visits, opioid use nearly doubled from 11.3% to 19.6%, whereas use of non-opioid analgesics remained unchanged (26%-29% of visits). Pain medications were associated with one-half of new musculoskeletal pain visits, with the use of nonopioid pharmacotherapies decreasing from 38% of visits (2000) to 29% of visits (2010). After adjusting for potentially confounding covariates, few patient, physician or practice characteristics were associated with the use of non-opioid rather than opioid analgesia. CONCLUSIONS: Increased opioid use during the past decade has not been accompanied by similar increases in non-opioid analgesics. Clinical alternatives to prescription opioids may be underutilized as a means of treating ambulatory non-malignant pain.
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META-ANALYSIS OF NEPHROTOXICITY IN PATIENTS WITH SOLID TUMORS TREATED WITH CISPLATIN VERSUS NON-CISPLATIN REGIMENS WITH SUB-GROUP ANALYSES BASED ON RENAL ELIGIBILITY CRITERIA
OBJECTIVES: Glomerular filtration rate (GFR) is known to better estimate renal function than serum creatinine (SCr), but SCr is commonly used when screening patients for inclusion into clinical trials of the nephrotoxic drug cisplatin. The objective of this meta-analysis was to indirectly compare incidence of nephrotoxicity in trials including cisplatin when renal function was assessed using either SCr or GFR for eligibility criteria. METHODS: A PubMed literature search identified randomized trials comparing cisplatin to non-cisplatin regimens. Included studies were performed from 1990-2010, used SCr or GFR as inclusion criteria, and reported incidence of WHO grade ≥3 nephrotoxic events for both treatment arms. Review articles, observational studies, phase 1 studies, non-randomized trials, studies without a comparator group, or studies not reported in English were excluded. Inverse variance weighted fixed effects (FE) and random effects (RE) methods were used to estimate the relative risk (RR) associated with cisplatin versus non-cisplatin regimens with sub-group analyses of studies using SCr, GFR, and either SCr or GFR for screening. RESULTS: A total of 2,359 studies were identified from the literature search and 29 studies met all inclusion and exclusion criteria (N=6,146 patients). Of these, 18 studies used SCr (N=4,146), 5 used GFR (N=993), and 6 used SCr or GFR (N=1,007) for screening. The overall RR for developing nephrotoxicity with cisplatin versus non-cisplatin treatment was 2.09 (95%CI 1.33-3.27, p=0.001). In sub-group analyses, the RR was 2.47 (95%CI 1.24-4.94, p=0.011) for SCr, 1.84 (95%CI 0.96-3.54, p=0.067) for GFR, and 1.88 (95%CI 0.49-7.26, p=0.359) for either SCr or GFR. Results did not vary between
